Hot Stocks
20:06 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Steve Wynn has resigned as finance chair of the Republican Party's fundraising arm, according to Reuters. This follows a news report saying he routinely subjected women who worked for him to unwanted sexual advances, the publication noted. 2. Trump national security officials are said to be considering a federal takeover of a portion of the nation's mobile network, according to Axios, citing sensitive documents obtained by the publication. The options laid out by the documents include U.S. government paying for and building the single network, or wireless providers building their own 5G networks, the report added. However, the latter is no option at all as a single centralized network is required to protect the country against China and other bad actors, a source said. Publicly traded wireless carriers include AT&T (T), Sprint (S), Verizon (VZ), and T-Mobile (TMUS). 3. While Goldman Sachs' (GS) overall financial results have been strong, with three out of four of its main business units thriving, trading has been reduced to crumbs, Jack Hough wrote in this week's edition of Barron's. Further, its competitor, Morgan Stanley (MS), surpassed it in market value for the first time in a decade, despite Goldman Sachs shares hitting a new 52-week high, he noted. Nonetheless, this makes an opportune time to buy Goldman Sachs stock, he argued, as the bank is more diversified than it was before the financial crisis and as it becomes more prosperous given expansion in mergers, lending and money management. 4. In its domestic debut weekend, 21st Century Fox's (FOXA) "Maze Runner: Death Cure" climbed to the top of box office with $23.5M from 3,787 theaters. The final installment of YA film franchise is also performing well overseas, grossing $62.6M for the weekend from 58 markets for a foreign total of $82M and $105.5M globally. The movie got a 44% from Rotten Tomatoes. 5. Biogen (BIIB), Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) saw positive mentions in Barron's, Snap-On (SNA) and First Solar (FSLR) were mentioned cautiously.
|
